PRC
DNLI icon

Pearl River Capital’s Denali Therapeutics DNLI Stock Holding History

Pearl River Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,175
Closed -$211K – 453
2021
Q3 		$211K Buy
+4,175
New +$235K 0.06% 370
2019
Q2 		– Sell
-294
Closed -$6K – 325
2019
Q1 		$6K Buy
+294
New +$6.15K 0.01% 320

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Pearl River Capital's DNLI Position: Q4 2021 in Review

Pearl River Capital sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 4,175 shares — an estimated $211K sold.

Pearl River Capital first reported a position in DNLI in Q1 2019 and held it in 2 quarters. The position peaked at $211K in Q3 2021. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

  • Pearl River Capital reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Pearl River Capital sold 4,175 Denali Therapeutics shares in Q4 2021, an estimated $211K.
  • Pearl River Capital first reported a position in Denali Therapeutics in Q1 2019 and held it in 2 quarters.
  • Pearl River Capital's Denali Therapeutics position peaked at $211K in Q3 2021.
  • 213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Pearl River Capital's 13F filing for Q4 2021, filed 11 Feb 2022.